While multiple factors can contribute to a business closing, the additional costs Pharmacy Benefit Managers impose on ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Spherico and the Syneos Health Value & Access team interviewed 25 pharmacy or medical directors. The fifth annual Payer Survey gives insight and understanding from national and regional payers, as ...